Replimune: A Misunderstood Contender In Oncolytics
Replimune's innovative cancer therapies, strong cash reserves, and FDA support position it to disrupt oncology markets. Click ...
Replimune Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update
U.S. Food and Drug Administration (FDA) recently accepted the Biologics License Application (BLA) for RP1 plus nivolumab in advanced melanoma for ...
hospitalhealthcare3d
Novel diagnostic tool iFRET helps predict immunotherapy outcomes in melanoma
New research highlights the potential of the novel diagnostic tool iFRET to determine immunotherapy outcomes in stage 2 ...
CAR T-Cell Therapy Market to Reach US$ 22.2 Billion By 2032 | Astute Analytica
CAR T-Cell therapy market growth is propelled by revolutionary results in treating certain blood cancers.New Delhi, Feb. 07, 2025 (GLOBE NEWSWIRE) -- The global CAR T-cell therapy market valuation is ...
Frontiers6d
Using Oncolytic Viruses in Cancer Immunity and Immunotherapy: Hepatocellular Carcinoma, Gastric Cancer, and Colorectal Cancer
Oncolytic viruses (OVs) are viruses that infect and kill cancer cells while sparing healthy tissue, making them a promising therapeutic option in cancer ...